If this message does not display properly, please click here to launch your browser.
| Three Late-Stage Obesity Therapies Close in on the Finish Line – Which Agents Will Have the Greatest Impact on the Market? — A Pharmacor Analyst Call from Decision Resources | ||||
Based on our 2009 Pharmacor Obesity report, Decision Resources is offering an exclusive analyst call entitled Three Late-Stage Obesity Therapies Close in on the Finish Line – Which Agents Will Have the Greatest Impact on the Market? Because this analyst call will feature report findings, it is ONLY available to purchasers of this report. Please contact us to learn how you can purchase this report and attend the analyst call. The failure of Sanofi-Aventis’s Acomplia has created a significant void in the obesity market—no new weight-loss therapies have launched in the United States since Abbott’s Meridia entered the market in 1998 and Roche’s Xenical (orlistat) launched in 1999. Owing to modest efficacy, poor safety and tolerability profiles and unfavorable reimbursement, neither Meridia nor Xenical ever achieved blockbuster status. Meanwhile, sales of GlaxoSmithKline’s Alli—an over-the-counter half-dose formulation of orlistat which became available in the U.S. market in 2007—peaked within months of its launch. However, at the 2009 annual meeting of The Obesity Society held last month, promising data were released for Arena Pharmaceuticals lorcaserin, Vivus’s Qnexa and Orexigen Therapeutics’ Contrave. These three novel obesity therapies have completed Phase III development and will soon be submitted for approval by the U.S. Food and Drug Administration. Following the conference, Decision Resources Director Donny Wong, Ph.D. surveyed 30 U.S. primary care physicians (PCPs) and interviewed key opinion leaders to determine their reaction to the news that emerged from the event. In this 15-minute analyst call, Dr. Wong will answer the following questions:
Dr. Wong will conduct a live Q & A session after the presentation. Registration Three Late-Stage Obesity Therapies Close in on the Finish Line – Which Agents Will Have the Greatest Impact on the Market? November 17, 2009 at 1 p.m. U.S. Eastern Time, 10 a.m. U.S. Pacific Time. To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below. In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com |
|
|||
Terms of Use | Privacy Policy | Contact Us | Careers |
||||
